Technology | February 16, 2012

Siemens’ New Biograph mCT PET/CT System Receives FDA Clearance

February 16, 2012 — Siemens Healthcare announced that the U.S. Food and Drug Administration (FDA) recently cleared the features associated with the new Biograph mCT positron emission tomography/computed tomography (PET/CT) scanner. The new Biograph mCT enables precise measurement of metabolic processes and data quantification, including the assessment of neurological disease and cancerous tissue, as well as cardiac blood flow (perfusion). Technological innovations and intelligent software solutions within the new PET/CT result in accurate, consistent quantitative assessments. With the new Biograph mCT, which was unveiled last November at the 2011 annual meeting of the Radiological Society of North America (RSNA) in Chicago, Siemens offers yet another paradigm in PET/CT — a goal of its recently announced global initiative, Agenda 2013.

Accuracy and reproducibility in PET quantification enable the physician to more precisely characterize cancer lesions, allowing for better staging and monitoring of changes in activity over time for more accurate assessment of treatment response. The ability to measure absolute myocardial blood flow in cardiology lets the physician to more accurately assess multi-vessel disease. In neurology, noninvasive assessment of the brain can potentially improve the diagnosis and management of patients who present with signs of dementia.

Siemens implemented these clinical requirements in the new Biograph mCT, which supports physicians in treating many neurological, oncological and cardiological diseases through earlier, more precise diagnosis, as well as in therapy planning and precise monitoring of disease progression. With this additional information, physicians are better equipped to make decisions with high certainty and initiate more patient-tailored therapies.

The latest Biograph mCT can provide additional information to aid in the diagnosis of dementia, which affects an estimated 35.6 million people worldwide and may affect as many as 115.4 million people by 2050. Alzheimer’s disease is the most frequently diagnosed form of dementia.

Technical innovations
With conventional technology, clinicians face the issue of variability in quantitative results due to software and hardware challenges. Engineered to overcome these technical and procedural obstacles, the new Biograph mCT offers accurate and reproducible quantification in PET/CT imaging by ensuring optimization of each element of the imaging chain – with an emphasis on the finest volumetric image resolution on the market, daily system calibration, accuracy of attenuation correction using automated co-registration algorithms, and more automated, user-independent and reproducible standardized uptake value (SUV) calculation methods for daily clinical practice.

The new Biograph mCT incorporates Siemens’ unique OptisoHD (High-Definition) Detector System, which features a fine volumetric resolution1 of only 87 mm. It is expected to ship in May 2012.

For more information: www.siemens.com/healthcare

Related Content

A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse

Figure 1. A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse from Amsterdam Ph.D. researcher Gustav Strijkers.

News | Magnetic Resonance Imaging (MRI) | June 07, 2019
The Amsterdam University Medical Center has won MR Solutions’ Image of the Year 2019 award for the best molecular...
BGN Technologies Introduces Novel Medical Imaging Radioisotope Production Method
News | Radiopharmaceuticals and Tracers | June 05, 2019
BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), introduced a novel method for...
RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform
News | Radiation Therapy | May 31, 2019
RefleXion Medical recently announced the opening of its new manufacturing facility at its headquarters in Hayward,...
Study Explores Magnetic Nanoparticles as Bimodal Imaging Agent for PET/MRI

Image courtesy of MR Solutions.

News | PET-MRI | May 23, 2019
Researchers from Bourgogne University in Dijon, France, showed that use of superparamagnetic iron oxide nanoparticles (...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Blue Earth Diagnostics Expands Access to Axumin in Europe
News | Radiopharmaceuticals and Tracers | May 13, 2019
Blue Earth Diagnostics announced expanded access to the Axumin (fluciclovine (18F)) imaging agent in Europe. The first...
Shine Medical Technologies Breaks Ground on U.S. Medical Isotope Production Facility

Image courtesy of Amen Clinics

News | Radiopharmaceuticals and Tracers | May 10, 2019 | Jeff Zagoudis, Associate Editor
Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in Janesville, Wis. U.S...
A 3-D printed tungsten X-ray system collimator. 3D printed, additive manufacturing for medical imaging.

A 3-D printed tungsten X-ray system collimator. The tungsten alloy powder is printed into the form desired and is laser fused so it can be machined and finished. Previously, making collimators from Tungsten was labor intensive because it required working with sheets of the metal to create the collimator matrix. 

Feature | Medical 3-D Printing | April 29, 2019 | By Steve Jeffery
In ...
NIH Study of Brain Energy Patterns Provides New Insights into Alcohol Effects

NIH scientists present a new method for combining measures of brain activity (left) and glucose consumption (right) to study regional specialization and to better understand the effects of alcohol on the human brain. Image courtesy of Ehsan Shokri-Kojori, Ph.D., of NIAAA.

News | Neuro Imaging | March 22, 2019
March 22, 2019 — Assessing the patterns of energy use and neuronal activity simultaneously in the human brain improve